HLA class II histocompatibility antigen, DX beta chain is a protein that in humans is encoded by the HLA-DQB2gene.[1][2]
References
↑Berdoz J, Tiercy JM, Rollini P, Mach B, Gorski J (May 1989). "Remarkable sequence conservation of the HLA-DQB2 locus (DX beta) within the highly polymorphic DQ subregion of the human MHC". Immunogenetics. 29 (4): 241–8. doi:10.1007/BF00717908. PMID2564844.
Piatier-Tonneau D, Gastinel LN, Amblard F, et al. (1991). "Interaction of CD4 with HLA class II antigens and HIV gp120". Immunogenetics. 34 (2): 121–8. doi:10.1007/BF00211424. PMID1869305.
Rosenstein Y, Burakoff SJ, Herrmann SH (1990). "HIV-gp120 can block CD4-class II MHC-mediated adhesion". J. Immunol. 144 (2): 526–31. PMID1967269.
Clayton LK, Sieh M, Pious DA, Reinherz EL (1989). "Identification of human CD4 residues affecting class II MHC versus HIV-1 gp120 binding". Nature. 339 (6225): 548–51. doi:10.1038/339548a0. PMID2543930.
Diamond DC, Sleckman BP, Gregory T, et al. (1988). "Inhibition of CD4+ T cell function by the HIV envelope protein, gp120". J. Immunol. 141 (11): 3715–7. PMID2846691.
Jonsson AK, Hyldig-Nielsen JJ, Servenius B, et al. (1987). "Class II genes of the human major histocompatibility complex. Comparisons of the DQ and DX alpha and beta genes". J. Biol. Chem. 262 (18): 8767–77. PMID3036828.
Andrieu JM, Even P, Venet A (1986). "AIDS and related syndromes as a viral-induced autoimmune disease of the immune system: an anti-MHC II disorder. Therapeutic implications". AIDS research. 2 (3): 163–74. doi:10.1089/aid.1.1986.2.163. PMID3489470.
Houlgatte R, Scarmato P, el Marhomy S, et al. (1994). "HLA class II antigens and the HIV envelope glycoprotein gp120 bind to the same face of CD4". J. Immunol. 152 (9): 4475–88. PMID7512597.
Chirmule N, McCloskey TW, Hu R, et al. (1995). "HIV gp120 inhibits T cell activation by interfering with expression of costimulatory molecules CD40 ligand and CD80 (B71)". J. Immunol. 155 (2): 917–24. PMID7541827.
Rowell JF, Stanhope PE, Siliciano RF (1995). "Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC". J. Immunol. 155 (1): 473–88. PMID7602119.
Chen YH, Böck G, Vornhagen R, et al. (1994). "HIV-1 gp41 binding proteins and antibodies to gp41 could inhibit enhancement of human Raji cell MHC class I and II expression by gp41". Mol. Immunol. 31 (13): 977–82. doi:10.1016/0161-5890(94)90092-2. PMID8084338.
Chirmule N, Wang XP, Hu R, et al. (1994). "Envelope glycoproteins of HIV-1 interfere with T-cell-dependent B cell differentiation: role of CD4-MHC class II interaction in the effector phase of T cell help". Cell. Immunol. 155 (1): 169–82. doi:10.1006/cimm.1994.1110. PMID8168144.
Callahan KM, Rowell JF, Soloski MJ, et al. (1993). "HIV-1 envelope protein is expressed on the surface of infected cells before its processing and presentation to class II-restricted T lymphocytes". J. Immunol. 151 (6): 2928–42. PMID8376762.
Beck S, Abdulla S, Alderton RP, et al. (1996). "Evolutionary dynamics of non-coding sequences within the class II region of the human MHC". J. Mol. Biol. 255 (1): 1–13. doi:10.1006/jmbi.1996.0001. PMID8568858.
Ruff AL, Guarnieri FG, Staveley-O'Carroll K, et al. (1997). "The enhanced immune response to the HIV gp160/LAMP chimeric gene product targeted to the lysosome membrane protein trafficking pathway". J. Biol. Chem. 272 (13): 8671–8. doi:10.1074/jbc.272.13.8671. PMID9079699.
Kanazawa S, Okamoto T, Peterlin BM (2000). "Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection". Immunity. 12 (1): 61–70. doi:10.1016/S1074-7613(00)80159-4. PMID10661406.